ETFs Holding CNAT »    CNAT Historical Stock Prices »
CNAT News Video: Fri, Dec 23, 2016, 1:03 PM — Friday Sector Leaders: Drugs, Biotechnology Stocks

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Conatus Pharmaceuticals is a biotechnology company focused on the development and commercialization of medicines to treat liver disease. Co. is developing emricasan, a pan-caspase protease inhibitor, for the treatment of patients with chronic liver disease. Emricasan is designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis and also provide further information on doses resulting in clinically relevant efficacy. Co. is also conducting a trial of emricasan in post-orthotopic liver transplant, recipients with hepatitis C virus, who achieved viral clearance, but who have residual fibrosis or cirrhosis in the transplanted liver. Self directed investors in Conatus Pharmaceuticals Inc will be interested in keeping up with all Conatus Pharmaceuticals Inc news they can find, both CNAT news originating from the company in the form of press releases, as well as seeing how independent media outlets are reporting news on CNAT. At RediNews, we simplify this task by presenting both CNAT news releases originating from Conatus Pharmaceuticals Inc itself, and CNAT news from a variety of media outlets. Visitors can browse this news online and through our CNAT RSS news feed.


CNAT News — Articles, Videos, & Press Releases

Conatus' (CNAT) Earnings, Revenues Miss Estimates in Q1
Monday, May 6, 2019, 12:53 PM — Zacks
Why Is Conatus (CNAT) Down 37.8% Since Last Earnings Report?
Sunday, April 7, 2019, 7:30 AM — Zacks
NASH Scorecard So Far This Year: A Look at the Hits & Misses
Friday, March 29, 2019, 7:31 AM — Zacks
First Week of CNAT May 17th Options Trading
Wednesday, March 20, 2019, 10:45 AM — Stock Options Channel
Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan
Wednesday, March 20, 2019, 9:10 AM — Zacks
How The Pieces Add Up: SPSM Headed For $35
Monday, March 18, 2019, 7:19 AM — ETF Channel
Implied Volatility Surging for Conatus (CNAT) Stock Options
Wednesday, March 13, 2019, 8:35 AM — Zacks
Conatus' (CNAT) Q4 Earnings Top Estimates, Emricasan in Focus
Monday, March 11, 2019, 8:57 AM — Zacks
Implied SPTM Analyst Target Price: $38
Thursday, February 14, 2019, 8:06 AM — ETF Channel
Conatus (CNAT) Completes Enrollment in Phase II NASH Study
Wednesday, February 13, 2019, 2:36 PM — Zacks
Add Up The Parts: IWC Could Be Worth $123
Wednesday, January 9, 2019, 7:53 AM — ETF Channel
First Week of February 15th Options Trading For Conatus Pharmaceuticals (CNAT)
Monday, January 7, 2019, 10:38 AM — Stock Options Channel
CNAT December 21st Options Begin Trading
Friday, September 28, 2018, 10:56 AM — Stock Options Channel
First Week of November 16th Options Trading For Conatus Pharmaceuticals (CNAT)
Thursday, September 27, 2018, 10:46 AM — Stock Options Channel
SPSM's Holdings Imply 10% Gain Potential
Monday, September 17, 2018, 7:54 AM — ETF Channel
We Did The Math SPSM Can Go To $36
Monday, July 30, 2018, 8:15 AM — ETF Channel
EQWS's Holdings Could Mean 11% Gain Potential
Tuesday, June 26, 2018, 7:44 AM — ETF Channel
First Week of CNAT August 17th Options Trading
Thursday, June 21, 2018, 10:47 AM — Stock Options Channel
Notable Tuesday Option Activity: CNAT, INSM, LIVN
Tuesday, June 12, 2018, 3:18 PM — Stock Options Channel
Analysts Forecast 11% Upside For EQWS
Thursday, May 24, 2018, 8:12 AM — ETF Channel
CNAT is categorized under the Healthcare sector; below are links to news for some other companies in the same sector:

LCI News

RediNews invites financial news content websites to integrate our XML content for web sites by integrating our RSS feeds found throughout our website wherever news and stock content is found, by clicking the RSS icon for any news page (which will look like this): . This dynamic content is ideal for any financial portal or web portal, from business content web sites to corporate portal intranets. Let RediNews be your content provider of free financial content for news, perfect for location on stock market chart pages by symbol, adding another element of dynamic stock market content to your financial portal. If your web page content already includes elements like SEC filings, screener pages, historical chart information, and other cobranded financial web content, then headlines from RediNews can supplement this dynamic financial content meaningfully.

CNAT News | | Copyright © 2013 - 2019, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.